SELLAS Life Sciences (SLS) is rated 'Hold' due to pending phase 3 REGAL data for GPS in AML after CR2, a major 2026 catalyst.
The Hematology Society of Taiwan yesterday said acute myeloid leukemia (AML), a fast-growing cancer of the blood and bone marrow, can progress quickly and aggressively and urged the government to ...
Stocktwits on MSN
SLS stock rises premarket ahead of cancer summit this month – investors eye phase 3 AML trial milestone
Sellas will present new data on its CDK9 inhibitor SLS009 at the American Association for Cancer Research (AACR) meeting on April 21. ・Preclinical findings showed SLS009 triggered leukemia cell death ...
PITTSBURGH, PA, UNITED STATES, March 10, 2026 /EINPresswire.com/ — FinScan, an Innovative Systems solution and leading provider of advanced AML and sanctions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results